Table 4.
Patients who discontinued and reasons for discontinuation. Others: death (2), hepatocarcinoma (1), pregnancy desire (2), loss to follow-up (1). (Chi-square test).
| Ustekinumab (Total)/Discontinuations n (%) | 148 (100%)/44 (29.72%) | Men (99) | Women (49) | p |
|---|---|---|---|---|
| Discontinuations | 44 (100%) | 28 (100%) | 16 (100%) | 0.024 |
| Primary failure | 6 (13.64%) | 5 (17.85%) | 1 (6.25%) | 0.230 |
| Secondary failure | 17 (38.64%) | 12 (42.85%) | 5 (31.25%) | 0.868 |
| Arthritis inefficacy | 10 (22.73%) | 5 (17.85%) | 5 (31.25%) | 0.082 |
| Adverse events | 5 (11.36%) | 3 (10.71%) | 2 (12.50%) | 0.747 |
| Others | 6 (13.64%) | 3 (10.71%) | 3 (18.75%) | 0.391 |